Vineti Appoints Christophe Suchet as Chief Product Officer
With cell and gene expertise in high demand, industry innovator will help expand the leading cloud-based software "platform of record" moving transformative personalized therapies through clinical trials and into mainstream medicine
SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Vineti, Inc., the leading digital traceability and orchestration software platform for cell and gene therapies, today announced the appointment of Christophe Suchet as Chief Product Officer. Mr. Suchet joins Vineti's industry-leading, multi-disciplinary team and will oversee product and ecosystem innovation and compliance. He will also be a key member of the team developing solutions for Vineti's cell and gene therapy clients and partners.
Mr. Suchet brings more than 20 years of information technology and senior executive experience consulting to, developing, and deploying innovative IT solutions for leading biopharmaceutical companies. Most recently, he served as Vice President of Information Technology for Kite Pharma, Inc. Under his stewardship, Kite Pharma developed the essential technology systems that helped Kite receive FDA approval in this new emerging cell therapy field, scale rapidly, offer an approved commercialized therapy in less than three years, and secure the landmark sale of the business for $11.9 billion to Gilead Sciences, Inc.
Prior to Kite Pharma, Mr. Suchet served as Vice President of IT at Pharmacyclics Inc., a clinical stage and commercial biopharmaceutical company. As a member of Pharmacyclics' Executive team, he oversaw the company's exponential growth and aligning of technology with business drivers. During Mr. Suchet's tenure, the company grew in two years from no product revenue, to $1 billion revenue, to acquisition by AbbVie for $21 billion.
Earlier in his career, Mr. Suchet served as Genentech's Director, IT Pharma Development Applications, and as IT Director, SAP Center of Excellence & Enterprise Applications, managing the company's portfolio of IT projects and applications across key business areas including safety, clinical operations, biostatistics, and project portfolio management. He was also Senior Manager, IT Applications at 3Com, Manager at KPMG Consulting, and Senior SAP Consultant at PricewaterhouseCoopers. Mr. Suchet received his M.S. in Biology and Economy from AgroParisTech and currently serves as an Advisory Board Member of the HMG CIO Executive Leadership Forum (San Francisco) and Advisor at Glyqa (Smart Therapeutics for Chronic Conditions).
With cell and gene therapy expertise in high demand, Mr. Suchet's experience and track record will bring invaluable, seasoned insights to Vineti and its customers.
"Christophe is an exceptional leader and pioneer in the critical technologies that enable the cell and gene therapy industry," said Amy DuRoss, CEO and Co-Founder of Vineti. "His experience further expands the impact of the Vineti platform and team, and we are pleased to have him join us as Product lead. As we scale our business, his experience knitting together complex, cloud-based systems will be invaluable in addressing the unique opportunities and challenges of moving new therapies through clinical trials and into mainstream medicine."
The Vineti digital "platform of record" powers next-generation therapies for cancer and other serious diseases by aligning, tracking, and documenting the entire cell therapy process, from ordering and logistics to manufacturing and clinical data. Vineti's software solution supports all the major stakeholders in the cell and gene therapy ecosystem, helping everyone from healthcare providers to biopharma and manufacturers exert efficiency and control while maintaining top-tier safety and compliance. Vineti's system helps therapy developers scale safely while controlling costs. The company's software platform is the only such independent system to have been part of a successful FDA cell therapy review, and is now in use in more than 65 leading medical centers and growing.
"Vineti has transformed the way clinical-phase and commercial-ready individualized medicines are developed and delivered at scale. Their state-of-the-art platform is a key reason why these vital therapies are now widely available. I look forward to further expanding patient access by assisting the company's ongoing efforts to lay the technology foundation for a personalized medicine ecosystem," commented Christophe Suchet.
About Vineti, Inc. Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. The Vineti "platform of record" integrates logistics, manufacturing and clinical data for individualized therapies to align and orchestrate the cell and gene therapy process and improve product performance overall. Caregivers and pharmaceutical pioneers are empowered to help more patients more effectively and safely, treatments are better understood and improved over time, and most importantly, there's an opportunity to provide greater health outcomes—and cures—to patients in need. The company is expanding rapidly, and the Vineti platform is now in use in more than 65 leading medical centers and growing. For more information, please visit www.vineti.com. Sign up to follow @vinetiworks on https://twitter.com/vinetiworks.
NOTE: Vineti and the Vineti logo are trademarks of Vineti, Inc. All other trademarks and service marks are the property of their respective owners.